Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal quarter and nine months ended December 31, 2019. The company is a clinical-stage biopharmaceutical developer with no commercial products or recurring product revenue.
Financial performance and position
| Metric | Three months ended Dec. 31 | Nine months ended Dec. 31 |
|---|---|---|
| Revenue | $0 in 2019 and 2018 | $0 in 2019 and 2018 |
| Research and development expense | $3.0 million vs. $5.3 million | $11.5 million vs. $13.3 million |
| General and administrative expense | $2.9 million vs. $1.9 million | $6.0 million vs. $5.5 million |
| Net loss | $6.0 million vs. $7.2 million | $17.5 million vs. $18.9 million |
| Net loss attributable to common stockholders | $6.3 million vs. $7.5 million | $18.4 million vs. $19.7 million |
| Loss per common share, basic and diluted | $0.15 vs. $0.24 | $0.43 vs. $0.75 |
- For the nine months, operating cash use was $13.2 million, compared with $11.0 million in the prior-year period. Financing activities provided $1.1 million; cash declined $12.0 million to $1.06 million.
- At December 31, 2019, current assets were $1.38 million and current liabilities were $2.94 million. Total assets were $5.33 million, total liabilities $11.43 million, and stockholders’ deficit $6.09 million. Accumulated deficit was $198.6 million.
- Reported current notes payable were $70,500. Operating lease liabilities totaled $4.10 million; accrued Series B preferred dividends were $4.69 million. The filing reports no off-balance-sheet arrangements.
Changes versus comparable periods
- Quarterly and nine-month net losses narrowed year over year, while cash used in operations increased. The nine-month R&D decline largely reflected the prior-year $4.25 million noncash charge for the PH94B and PH10 licenses and option; quarterly R&D also fell as the AV-101 Elevate Study concluded.
- G&A increased, including $826,900 of noncash warrant-modification expense in the quarter. Increased stock-based compensation also contributed; lower investor and public-relations expense partly offset these items.
- Common shares outstanding rose from 42.76 million at March 31 to 44.23 million at December 31, 2019. The company also modified or issued warrants, adding potential dilution.
Programs, outlook, and significant risks
- PH94B: Management was preparing for Phase 3 development for social anxiety disorder. The filing cites earlier positive Phase 2 results and positive pilot Phase 3 experience, but further pivotal studies and regulatory approval remain necessary.
- PH10: Management planned Phase 2b development for major depressive disorder after an exploratory 30-patient Phase 2a study reported rapid-onset effects sustained over eight weeks. These findings are early-stage and do not establish efficacy in later trials.
- AV-101: The 199-patient Elevate Phase 2 study did not show separation from placebo on its primary endpoint for adjunctive MDD treatment. The company cited potentially inadequate active-metabolite levels in the brain and planned further preclinical work, including study of AV-101 with probenecid. A separate 10-person Baylor target-engagement study reported a biomarker response at the higher dose; this is not evidence of clinical efficacy.
- Management expected continued losses and negative operating cash flows. It stated that December cash plus approximately $2.68 million of net proceeds from a January 2020 offering would not fund planned operations for the next 12 months, creating substantial doubt about the company’s ability to continue as a going concern. Additional financing or collaboration funding is needed; availability and terms are uncertain. Failure to raise funds could force reductions, delays, or discontinuation of research programs.
- The January 2020 financing included 3,870,077 common shares sold for $2.75 million gross and warrants for an equal number of shares, exercisable at $0.73 after six months. These securities may contribute to future dilution.
- After quarter-end, Nasdaq notified the company that it did not meet the $1.00 minimum bid-price requirement, with an initial compliance deadline of July 29, 2020. Delisting could impair liquidity and access to capital.
- Management identified continuing risks from clinical and regulatory uncertainty, reliance on contract research and manufacturing organizations, competition, intellectual-property challenges, and dependence on additional financing. Disclosure controls were deemed effective, but previously reported material weaknesses in segregation of duties and accounting software remained unremediated.
Important facts for investors to verify
- Current cash runway, subsequent spending, and whether financing sufficient for the next 12 months has been secured.
- Terms, net proceeds, warrant dilution, and any further financing or licensing transactions after the January 2020 offering.
- Timing, funding, regulatory alignment, and eventual results of planned PH94B and PH10 trials; the AV-101 program’s next steps after the Elevate result.
- Nasdaq bid-price compliance status and any effect on the company’s ability to raise capital.
- Progress in remediating internal-control material weaknesses and the potential dilution from outstanding preferred stock, options, and warrants.